Matthew Cannon

Matthew Cannon

Auto-generated profile, based on publicly available information

Matthew Cannon

Institute for Genomic Medicine, Nationwide Children’s Hospital , Columbus, OH 43205

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MCMatthew Cannon
Matthew Cannon
JSJames Stevenson
James Stevenson
KSKathryn Stahl
Kathryn Stahl
RBRohit Basu
Rohit Basu
ACAdam Coffman
Adam Coffman
AWAlex H Wagner
Alex H Wagner
The Drug–Gene Interaction Database (DGIdb, https://dgidb.org) is a publicly accessible resource that aggregates genes or gene products, drugs and drug–gene interaction records to drive hypothesis generation and discovery for clinicians and researchers. DGIdb 5.0 is the latest release and includes substantial architectural and functional updates to support integration into clinical and drug discovery pipelines. The DGIdb service architecture has been split into separate client and server applications, enabling consistent data access for users of both the application programming interface (API) and web interface. The new interface was developed in ReactJS, and includes dynamic visualizations and consistency in the display of user interface elements. A GraphQL API has been added to support customizable queries for all drugs, genes, annotations and associated data. Updated documentation provides users with example queries and detailed usage instructions for these new features. In addition, six sources have been added and many existing sources have been updated. Newly added sources include ChemIDplus, HemOnc, NCIt (National Cancer Institute Thesaurus), Drugs@FDA, HGNC (HUGO Gene Nomenclature Committee) and RxNorm. These new sources have been incorporated into DGIdb to provide additional records and enhance annotations of regulatory approval status for therapeutics. Methods for grouping drugs and genes have been expanded upon and developed as independent modular normalizers during import. The updates to these sources and grouping methods have resulted in an improvement in FAIR (findability, accessibility, interoperability and reusability) data representation in DGIdb.

16 September 2022 in Science Advances
Verified
Journal Article
Open access
PZPu Zhang
Pu Zhang
LBLindsey T. Brinton
Lindsey T. Brinton
MGMehdi Gharghabi
Mehdi Gharghabi
SSSteven Sher
Steven Sher
KWKatie Williams
Katie Williams
RLRosa Lapalombella
Rosa Lapalombella
Using a genome-wide CRISPR screen, we identified CDK9 , DHODH , and PRMT5 as synthetic lethal partners with gilteritinib treatment in fms-like tyrosine kinase 3 ( FLT3 )–internal tandem duplication (ITD) acute myeloid leukemia (AML) and genetically and pharmacologically validated their roles in gilteritinib sensitivity. The presence of FLT3 -ITD is associated with an increase in anaerobic glycolysis, rendering leukemia cells highly sensitive to inhibition of glycolysis. Supportive of this, our data show the enrichment of single guide RNAs targeting 28 glycolysis-related genes upon gilteritinib treatment, suggesting that switching from glycolysis to oxidative phosphorylation (OXPHOS) may represent a metabolic adaption of AML in gilteritinib resistance. CDK9i/FLT3i, DHODHi/FLT3i, and PRMT5i/FLT3i pairs mechanistically converge on OXPHOS and purine biosynthesis blockade, implying that targeting the metabolic functions of these three genes and/or proteins may represent attractive strategies to sensitize AML to gilteritinib treatment. Our findings provide the basis for maximizing therapeutic impact of FLT3 -ITD inhibitors and a rationale for a clinical trial of these novel combinations.

1 May 2007 in Reproduction
Verified
Journal Article
Open access
MCMatthew J Cannon
Matthew J Cannon
JDJohn S Davis
John S Davis
JPJoy L Pate
Joy L Pate
Cells expressing class II major histocompatibility complex (MHC) molecules are found within the corpus luteum (CL) of several species. Expression and localization of class II MHC molecules in the bovine CL were examined in the present study. Immunohistochemical evaluation revealed class II MHC molecules on single cells in early CL (days 4 and 5 post-estrus). Two class II MHC-expressing cell types were observed in midcycle CL (days 10–12 post-estrus), single cells similar to those observed in the early CL, and endothelial cells. Not all endothelial cells expressed class II MHC, and further investigation revealed expression of only one type of class II MHC molecule, DR, on endothelial cells. Class II MHC was also localized to endothelial cells in late CL (day 18 post-estrus). Steroidogenic luteal cells were negative for class II MHC throughout the estrous cycle. Quantitative RT-PCR revealed higher (P < 0.05) concentrations of mRNA encoding the α-subunit of DR (DRA) in late CL when compared with those in the early CL. DRA mRNA abundance was also measured in cultures of mixed luteal and luteal endothelial (CLENDO) cells, in the presence or absence of tumor necrosis factor-α (TNF). No differences were found in the DRA mRNA concentration between mixed luteal and CLENDO cell cultures, and TNF had no effect on DRA mRNA concentration in both cell types. Expression of DR by endothelial cells of the midcycle CL may induce anergy of T lymphocytes, or stimulate them to secrete products that enhance normal luteal function.

4 October 2023 in JAMIA Open
Verified
Journal Article
Open access
PDF file
MCMatthew Cannon
Matthew Cannon
JSJames Stevenson
James Stevenson
KKKori Kuzma
Kori Kuzma
SKSusanna Kiwala
Susanna Kiwala
JWJeremy L Warner
Jeremy L Warner
AWAlex H Wagner
Alex H Wagner
Objective: The diversity of nomenclature and naming strategies makes therapeutic terminology difficult to manage and harmonize. As the number and complexity of available therapeutic ontologies continues to increase, the need for harmonized cross-resource mappings is becoming increasingly apparent. This study creates harmonized concept mappings that enable the linking together of like-concepts despite source-dependent differences in data structure or semantic representation. Materials and Methods: For this study, we created Thera-Py, a Python package and web API that constructs searchable concepts for drugs and therapeutic terminologies using 9 public resources and thesauri. By using a directed graph approach, Thera-Py captures commonly used aliases, trade names, annotations, and associations for any given therapeutic and combines them under a single concept record. Results: We highlight the creation of 16 069 unique merged therapeutic concepts from 9 distinct sources using Thera-Py and observe an increase in overlap of therapeutic concepts in 2 or more knowledge bases after harmonization using Thera-Py (9.8%-41.8%). Conclusion: We observe that Thera-Py tends to normalize therapeutic concepts to their underlying active ingredients (excluding nondrug therapeutics, eg, radiation therapy, biologics), and unifies all available descriptors regardless of ontological origin.

7 January 2026 in Bioinformatics Advances
Verified
Journal Article
Open access
MCMatthew Cannon
Matthew Cannon
WGWesley Goar
Wesley Goar
ILIn-Hee Lee
In-Hee Lee
JSJames Stevenson
James Stevenson
AHAmy Heiser
Amy Heiser
AWAlex H Wagner
Alex H Wagner
Rapid advancements in technology have led to an increased use of artificial intelligence (AI) technologies in medicine and bioinformatics research. In anticipation of this, the National Institutes of Health (NIH) assembled the Bridge to Artificial Intelligence (Bridge2AI) consortium to coordinate development of “AI-ready” datasets that can be leveraged by AI models to address grand challenges in human health and disease. The widespread availability of genome sequencing technologies for biomedical research presents a key data type for informing AI models, necessitating that genomics data sets are “AI-ready.” To this end, the Genomic Information Standards Team (GIST) of the Bridge2AI Standards Working Group has documented a set of recommendations for maintaining AI-ready genomics datasets. In this report, we describe recommendations for the collection, storage, identification, and proper use of genomics datasets to enable them to be considered “AI-ready” and thus drive new insights in medicine through AI and machine learning applications.

22 August 2026 in Bioinformatics
Verified
Journal Article
Open access
LSLars Schimmelpfennig
Lars Schimmelpfennig
MCMatthew Cannon
Matthew Cannon
QCQuentin Cody
Quentin Cody
JMJoshua McMichael
Joshua McMichael
ACAdam C Coffman
Adam C Coffman
OGObi L Griffith
Obi L Griffith
Summary: The druggable genome encompasses the genes that are known or predicted to interact with drugs. The Drug-Gene Interaction Database (DGIdb) provides an integrated resource for discovering and contextualizing these interactions, supporting a broad range of research and clinical applications. DGIdb is currently accessed through structured web interfaces and API calls, requiring users to translate natural-language questions into database-specific query patterns. To allow for the use of DGIdb through natural language, we developed the DGIdb Model Context Protocol (MCP) server, which allows large language models (LLMs) access to up-to-date information through the DGIdb API. We demonstrate that the MCP server improves an LLM’s ability to answer questions requiring accurate, up-to-date biomedical knowledge drawn from structured external resources. Availability and implementation: The DGIdb MCP server is detailed at https://github.com/dgidb/dgidb-mcp-server and includes instructions for accessing the server through the Claude desktop app.